Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MVA-MAGEA3 |
Synonyms | |
Therapy Description |
MVA-MAGEA3 is a cancer vaccine comprising a modified vaccinia Ankara virus engineered to express MAGE-A3, which potentially increases antitumor immune response (PMID: 34479921). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MVA-MAGEA3 | MVA MAGEA3|MVAMAGEA3 | MVA-MAGEA3 is a cancer vaccine comprising a modified vaccinia Ankara virus engineered to express MAGE-A3, which potentially increases antitumor immune response (PMID: 34479921). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04908111 | Phase Ib/II | MVA-MAGEA3 ChAdOx1-MAGEA3-NYESO | A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 | Suspended | GBR | 0 |